Evidence map›Paper›PMID 28656463›Full record

Observational studyEuropean radiology2017

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.

Arash Latifoltojar, Margaret Hall-Craggs, Alan Bainbridge, Neil Rabin, Rakesh Popat, Ali Rismani, Shirley D'Sa, Nikolaos Dikaios, Magdalena Sokolska, Michela Antonelli and 5 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  15. MAGORINO: Magnitude-only fat fraction and RMagnetic resonance in medicine · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Arash LatifoltojarCentre for Medical Imaging, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London, UK, NW1 2HE.
Margaret Hall-CraggsCentre for Medical Imaging, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London, UK, NW1 2HE.
Alan BainbridgeDepartment of Medical Physics and Bioengineering, University College London Hospital, London, UK.
Neil RabinDepartment of Haematology, University College London Hospital, London, UK.
Rakesh PopatDepartment of Haematology, University College London Hospital, London, UK.
Ali RismaniDepartment of Haematology, University College London Hospital, London, UK.
Shirley D'SaDepartment of Haematology, University College London Hospital, London, UK.
Nikolaos DikaiosCentre for Medical Imaging, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London, UK, NW1 2HE.
Magdalena SokolskaDepartment of Medical Physics and Bioengineering, University College London Hospital, London, UK.
Michela AntonelliTranslational Imaging Group, Centre for Medical Imaging Computing, University College London, London, UK.
Sebastien OurselinTranslational Imaging Group, Centre for Medical Imaging Computing, University College London, London, UK.
Kwee YongDepartment of Haematology, University College London Hospital, London, UK.
Stuart A TaylorCentre for Medical Imaging, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London, UK, NW1 2HE.
Steve HalliganCentre for Medical Imaging, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London, UK, NW1 2HE.
Shonit PunwaniCentre for Medical Imaging, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London, UK, NW1 2HE. shonit.punwani@gmail.com.
University College London · GBUniversity College Hospital · GB

Funding

Cancer Research UK 16463
6 · The paper itself

Abstract

objectivesTo evaluate whole-body MRI (WB-MRI) parameters significantly associated with treatment response in multiple myeloma (MM).

methodsTwenty-one MM patients underwent WB-MRI at diagnosis and after two cycles of chemotherapy. Scans acquired at 3.0 T included T2, diffusion-weighted-imaging (DWI) and mDixon pre- and post-contrast. Twenty focal lesions (FLs) matched on DWI and post-contrast mDixon were selected for each time point. Estimated tumour volume (eTV), apparent diffusion coefficient (ADC), enhancement ratio (ER) and signal fat fraction (sFF) were derived. Clinical treatment response to chemotherapy was assessed using conventional criteria. Significance of temporal parameter change was assessed by the paired t test and receiver operating characteristics/area under the curve (AUC) analysis was performed. Parameter repeatability was assessed by interclass correlation (ICC) and Bland-Altman analysis of 10 healthy volunteers scanned at two time points.

resultsFifteen of 21 patients responded to treatment. Of 254 FLs analysed, sFF (p < 0.0001) and ADC (p = 0.001) significantly increased in responders but not non-responders. eTV significantly decreased in 19/21 cases. Focal lesion sFF was the best discriminator of treatment response (AUC 1.0). Bone sFF repeatability was excellent (ICC 0.98) and better than bone ADC (ICC 0.47).

conclusionWB-MRI derived focal lesion sFF shows promise as an imaging biomarker of treatment response in newly diagnosed MM. KEY POINTS: • Bone signal fat fraction using mDixon is a robust quantifiable parameter • Fat fraction and ADC significantly increase in myeloma lesions responding to treatment • Bone lesion fat fraction is the best discriminator of myeloma treatment response.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBortezomibDiffusion Magnetic Resonance ImagingFemaleHumansMaleMiddle AgedMultiple MyelomaProspective StudiesTreatment OutcomeWhole Body ImagingAntineoplastic AgentsBortezomibBortezomibMRIMultiple myelomaResponse monitoringWhole body

Identifiers

PMID28656463
PMCPMC5674123
OpenAlexW2729221450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.